Page last updated: 2024-08-24

glucose, (beta-d)-isomer and Bile Duct Cancer

glucose, (beta-d)-isomer has been researched along with Bile Duct Cancer in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Gu, Y; Li, W; Ming, Y; Xiao, L; Zheng, Z1
Brell, J; Chak, A; Dowlati, A; Fu, P; Hoppel, CL; Ingalls, S; Ivy, P; Krishnamurthi, S; Posey, J; Ramanathan, RK; Rath, L; Remick, SC1

Trials

1 trial(s) available for glucose, (beta-d)-isomer and Bile Duct Cancer

ArticleYear
Phase II and pharmacokinetic trial of rebeccamycin analog in advanced biliary cancers.
    Cancer chemotherapy and pharmacology, 2009, Volume: 65, Issue:1

    Topics: Aged; Antineoplastic Agents; Bile Duct Neoplasms; CA-19-9 Antigen; Carbazoles; Female; Fever; Gallbladder Neoplasms; Glucosides; Humans; Male; Middle Aged; Neutropenia; Survival Rate; Thrombocytopenia

2009

Other Studies

1 other study(ies) available for glucose, (beta-d)-isomer and Bile Duct Cancer

ArticleYear
Corilagin suppresses cholangiocarcinoma progression through Notch signaling pathway in vitro and in vivo.
    International journal of oncology, 2016, Volume: 48, Issue:5

    Topics: Animals; Antineoplastic Agents; Bile Duct Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cholangiocarcinoma; Disease Progression; Gene Expression Regulation, Neoplastic; Glucosides; Humans; Hydrolyzable Tannins; In Vitro Techniques; Mice; Mice, Nude; Receptors, Notch; Signal Transduction; Transcription Factor HES-1; Xenograft Model Antitumor Assays

2016